Nykode Therapeutics AS (VACBF)
OTCMKTS · Delayed Price · Currency is USD
0.3800
0.00 (0.00%)
At close: Feb 10, 2026
Nykode Therapeutics AS Employees
Nykode Therapeutics AS had 62 employees as of September 30, 2025. The number of employees decreased by 123 or -66.49% compared to the same quarter last year.
Employees
62
Change
-123
Growth
-66.49%
Revenue / Employee
$118,484
Profits / Employee
-$177,452
Market Cap
133.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 62 | -123 | -66.49% | 62 | 0 |
| Jun 30, 2025 | 68 | -111 | -62.01% | 68 | 0 |
| Mar 31, 2025 | 75 | -101 | -57.39% | 75 | 0 |
| Dec 31, 2024 | 136 | -37 | -21.39% | 135 | 1 |
| Sep 30, 2024 | 185 | 17 | 10.12% | 185 | 0 |
| Jun 30, 2024 | 179 | 14 | 8.48% | 179 | 0 |
| Mar 31, 2024 | 176 | 18 | 11.39% | 176 | 0 |
| Dec 31, 2023 | 173 | 22 | 14.57% | 171 | 2 |
| Sep 30, 2023 | 168 | 21 | 14.29% | 168 | 0 |
| Jun 30, 2023 | 165 | 30 | 22.22% | 165 | 0 |
| Mar 31, 2023 | 158 | 30 | 23.44% | 158 | 0 |
| Dec 31, 2022 | 151 | 51 | 51.00% | 149 | 2 |
| Sep 30, 2022 | 147 | 60 | 68.97% | 147 | 0 |
| Jun 30, 2022 | 135 | 60 | 80.00% | 135 | 0 |
| Mar 31, 2022 | 128 | 67 | 109.84% | 128 | 0 |
| Dec 31, 2021 | 100 | 49 | 96.08% | 99 | 1 |
| Sep 30, 2021 | 87 | 51 | 141.67% | 87 | 0 |
| Jun 30, 2021 | 75 | 45 | 150.00% | 75 | 0 |
| Mar 31, 2021 | 61 | 35 | 134.62% | 61 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Nykode Therapeutics AS News
- 2 months ago - Nykode Therapeutics AS (VACBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer - GlobeNewsWire
- 1 year ago - Nykode Therapeutics - Quarterly report Q1 2024 - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer - GlobeNewsWire